Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Phase III randomized controlled trial with adequate sample size (2,777 participants) and active comparator, demonstrating comparable safety profiles between MenACYW-TT and MenACWY-CRM with systematic adverse event monitoring; rigorous design supports but does not alone change clinical practice.
Network meta-analysis of 17 trials confirms differential serotype-specific immunogenicity between higher-valent pneumococcal vaccines, with PCV15 showing mostly superior responses.
Expert consensus statement synthesizing regional surveillance data and literature to guide post-pandemic pneumococcal vaccination policy in Latin America, but without new primary data or quantified efficacy evidence.
This mini-review synthesizes evidence on disease burden and immune vulnerability in high-risk child populations to inform targeted PCV strategies, but contains no new primary data or comparative trials.